Amgen's Rare Disease Pipeline: What 2026 Readouts Mean for the Horizon Acquisition

Amgen bought Horizon to solve a specific problem. Its legacy portfolio — Enbrel, Neulasta, Epogen — was decaying under biosimilar pressure. Its mid-pipeline was mostly oncology, a crowded and capital-intensive therapeutic area. Rare disease offered three things Amgen wanted: orphan drug pricing power, longer exclusivity windows, and a patient population too small to attract biosimilar competition for a decade or more.

Horizon brought three commercial anchors. Tepezza (teprotumumab) for thyroid eye disease did $1.97 billion in 2022 and was the stated reason for the deal premium. Krystexxa (pegloticase) for chronic refractory gout added roughly $800 million. Uplizna (inebilizumab) for neuromyelitis optica spectrum disorder contributed a smaller but faster-growing base. Together, those three products generated most of the cash flow that was supposed to justify the acquisition price.

The 2025 numbers tell a different story.

The Post-Acquisition Reality Check

Tepezza's decline is the real problem. The drug's 2022 launch trajectory was steep enough that most post-deal models assumed it would clear $2.5 billion by 2025. Instead, it has contracted for six straight quarters. Multiple factors are at work — patient identification has plateaued, second-course prescribing rates are lower than Horizon's original models assumed, and the Medicare Part B injection reimbursement shifts in 2024 compressed margins on outpatient administration. None of these are easy to reverse.

Krystexxa's growth has been incremental despite a label expansion for methotrexate co-administration that was supposed to meaningfully expand the eligible patient population. The underlying issue is real-world uptake: pegloticase requires biweekly infusions in a specialty setting, and rheumatologists have been slower to adopt the co-administration protocol than Horizon's pre-deal decks suggested.

Uplizna is the anomaly. NMO is an ultra-rare disease — roughly 15,000 diagnosed patients in the US — but Uplizna's share of treatment-eligible patients has grown from single digits to mid-30s. More importantly, Uplizna's label is expanding into generalized myasthenia gravis (an indication with ten times NMO's patient base) and IgG4-related disease. Those label expansions are the reason Amgen still frames the Horizon deal as on-track.

The Three 2026–2027 Catalysts That Decide Everything

Three Phase 3 readouts over the next 18 months will determine whether the Horizon pipeline justifies the deal math.

Catalyst one: Uplizna in generalized myasthenia gravis

The MINT trial, a Phase 3 evaluating Uplizna in gMG, is expected to report topline data in Q3 2026. gMG affects roughly 100,000 US patients — nearly seven times NMO's eligible population. A positive readout would expand Uplizna's addressable market by a factor of approximately 5x, driven by a much larger diagnosed-prevalence base and shorter diagnostic journeys. Consensus analyst models assume a peak revenue contribution of $1.5B to $2.2B if the indication is added.

The clinical risk is moderate. Uplizna's anti-CD19 mechanism has strong biological rationale in gMG, and open-label Phase 2 data suggested meaningful efficacy. The commercial risk is higher — argenx's Vyvgart is already approved for gMG and has built significant physician familiarity. Uplizna will be launching into a competitive market, not an open field.

Catalyst two: Amgen's internal rocatinlimab program in alopecia areata

Rocatinlimab (an OX40 inhibitor) is Amgen's internally-developed asset that the company has been positioning as a rare-disease multi-indication platform. The Phase 3 ROCKET trial in severe alopecia areata has topline data expected in Q1 2027. Peak revenue models sit between $800M and $1.4B, with upside if a follow-on atopic dermatitis indication (currently Phase 2) converts.

This one is important for a different reason. Horizon's legacy pipeline was thin on internal R&D — the company had made its money on licensed and acquired assets. Rocatinlimab is Amgen demonstrating that it can develop rare-disease originators in-house using the infrastructure it bought. A clean readout signals the Horizon acquisition has become a platform, not just a portfolio purchase.

Catalyst three: Amgen's Krystexxa follow-on in refractory chronic gout

Amgen's AMG-133 program in refractory gout is a next-generation uricase designed to resolve the immunogenicity and dosing issues that have held back Krystexxa uptake. Phase 3 readout is expected in Q2 2027. If successful, the candidate could cannibalize Krystexxa but at higher market penetration and with a more palatable administration profile.

The strategic question is whether a successful AMG-133 readout extends the Horizon rare-disease franchise into the 2030s or simply replaces existing Krystexxa revenue at similar scale. Management framing on recent earnings calls has suggested the former. Analyst models are split.

What Pharmacy and Investment Decision-Makers Should Watch

The frame matters more than any single readout. If Uplizna hits gMG, Amgen books meaningful revenue expansion without further M&A and the Horizon deal looks prescient. If rocatinlimab succeeds, Amgen has proven that its rare-disease infrastructure is a platform for internal R&D — a materially higher-value asset than a portfolio of acquired drugs. If AMG-133 hits in gout, Amgen has extended the rare-disease franchise's exclusivity runway into the 2030s.

If all three fail or deliver mixed results, the Horizon acquisition price of $28.3 billion starts looking like Bristol-Myers Squibb's Celgene deal — a richly-priced portfolio purchase that delivered solid cash flow but not strategic transformation. Amgen would have spent the equivalent of three years of free cash flow to acquire a declining legacy portfolio and a pipeline that didn't perform.

The most important signal is not any single Phase 3 readout but whether management starts trimming peak revenue guidance for the MINT trial or the ROCKET trial before topline data arrives. Biotech executives don't reset their own guidance unless internal data suggests they need to. Watch the next three earnings calls for language shifts — that's where the real story will be visible before the data actually prints.